Navigation Links
ADVENTRX Signs Definitive Agreement to Acquire SynthRx Inc.
Date:2/14/2011

SAN DIEGO, Feb. 14, 2011 /PRNewswire/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced that it has entered into a definitive agreement to acquire SynthRx, Inc. (SynthRx), a private biotechnology company developing a purified form of a rheologic and antithrombotic agent, poloxamer 188 (188).

"The acquisition of SynthRx will be a transformative event for ADVENTRX, adding another late-stage asset to our pipeline," stated Brian M. Culley, Chief Executive Officer of ADVENTRX. "The all-stock, milestone-based deal structure is a win for ADVENTRX and its stockholders in that it allows us to retain our cash for development activities and, other than a modest upfront equity payment, ensures we pay only as the 188 program achieves success.  I'm pleased that we would have the data from the planned phase 3 study in-hand while having paid less than 25% of the total deal consideration."

"The 188 program will fit well with our existing assets and provide several exciting development opportunities. We would plan to meet with the FDA later this year to reach agreement on a protocol for a pivotal phase 3 study for the treatment of sickle cell crisis in a pediatric population, for which 188 has orphan drug designation. Sickle cell patients are an under-served population suffering from an excruciatingly painful condition with limited palliative options. Beyond sickle cell, we believe 188 has clinical benefits in other acute events related to microvascular-flow abnormalities, such as heart attack, stroke and hemorrhagic shock," Mr. Culley continued.  

Under the terms of the all-stock transaction, SynthRx would become a wholly-owned subsidiary of ADVENTRX in exchange for shares of ADVENTRX common stock representing, in the aggregate, an approximately 4% ownership stake in ADVENTRX.  SynthRx stakeholders also would be entitled to receive additional shar
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ADVENTRX to Provide Update Regarding Pipeline Expansion Efforts
2. ADVENTRX Pharmaceuticals to Present at the 13th Annual BIOCEO & Investor Conference on February 15
3. ADVENTRX Pharmaceuticals Receives PDUFA Date for Exelbine™ NDA
4. ADVENTRX Pharmaceuticals Announces Closing of $22.5 Million Financing
5. ADVENTRX Pharmaceuticals Announces Capital Raise of $22.5 Million
6. ADVENTRX Announces Signing of Term Sheet for Acquisition of Poloxamer-Based Therapeutics
7. ADVENTRX Pharmaceuticals to Present at the 4TH Annual OneMedForum Business Development and Investment Conference on January 11
8. ADVENTRX Requests Meeting with FDA to Discuss ANX-514 Study
9. ADVENTRX Reports Third Quarter Financial Results
10. ADVENTRX to Present at the Wall Street Analyst Forum 21st Annual Institutional Investor Conference on November 11
11. ADVENTRX Submits Exelbine™ New Drug Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Mich. , Sept. 19, 2014  Diplomat, the ... of David Dreyer to the Board of ... independent director and will also serve as chair of ... almost 30 years of accounting, financial, compliance and operating ... Mr. Dreyer has served as chief financial officer, chief ...
(Date:9/19/2014)... , Sept. 19, 2014 UBM Medica ... a leading online community to help oncologists and other ... available regarding the use of targeted therapies and immunotherapies, ... research and treatment.  Every September, ... way to raise awareness about blood cancers—helping to increase ...
(Date:9/19/2014)... 2014 Five MinuteClinic walk-in medical clinics are opening inside ... area. Three clinics opened in Memphis and ... will be added in Springfield on September ... is expected to open October 22.  MinuteClinic is the largest and ... United States . The Memphis ...
Breaking Medicine Technology:David Dreyer Appointed to Diplomat Board of Directors 2OncoTherapy Network Highlights National Blood Cancer Awareness Month 2OncoTherapy Network Highlights National Blood Cancer Awareness Month 3OncoTherapy Network Highlights National Blood Cancer Awareness Month 4MinuteClinic Walk-in Medical Clinics Opening in Memphis 2MinuteClinic Walk-in Medical Clinics Opening in Memphis 3
... , , , , , , , , , ... and LAUSANNE, Switzerland , February 4 ... Debiopharm Group (Debiopharm), a Swiss-based global,biopharmaceutical group of companies with ... medical needs, announce the launch by,Ipsen in France ...
... , REDWOOD CITY, Calif. , Feb. ... financial results for the year ended December 31, 2009 , which ... cash flow positive. , Total revenue for the fourth quarter of 2009 ... in the fourth quarter of 2008.  Product revenue from the Onco type ...
Cached Medicine Technology:Launch of Ipsen's Decapeptyl(R) 6-Month Formulation (LP 22.5 mg) in France for the Treatment of Locally Advanced or Metastatic Hormone-Dependent Prostate Cancer 2Launch of Ipsen's Decapeptyl(R) 6-Month Formulation (LP 22.5 mg) in France for the Treatment of Locally Advanced or Metastatic Hormone-Dependent Prostate Cancer 3Launch of Ipsen's Decapeptyl(R) 6-Month Formulation (LP 22.5 mg) in France for the Treatment of Locally Advanced or Metastatic Hormone-Dependent Prostate Cancer 4Launch of Ipsen's Decapeptyl(R) 6-Month Formulation (LP 22.5 mg) in France for the Treatment of Locally Advanced or Metastatic Hormone-Dependent Prostate Cancer 5Launch of Ipsen's Decapeptyl(R) 6-Month Formulation (LP 22.5 mg) in France for the Treatment of Locally Advanced or Metastatic Hormone-Dependent Prostate Cancer 6Genomic Health Announces Year-End 2009 Financial Results 2Genomic Health Announces Year-End 2009 Financial Results 3Genomic Health Announces Year-End 2009 Financial Results 4Genomic Health Announces Year-End 2009 Financial Results 5Genomic Health Announces Year-End 2009 Financial Results 6Genomic Health Announces Year-End 2009 Financial Results 7Genomic Health Announces Year-End 2009 Financial Results 8Genomic Health Announces Year-End 2009 Financial Results 9Genomic Health Announces Year-End 2009 Financial Results 10Genomic Health Announces Year-End 2009 Financial Results 11Genomic Health Announces Year-End 2009 Financial Results 12
(Date:9/19/2014)... 19, 2014 Follow us on ... the medical imaging market, are engineered to enhance the ... the past three decades have expanded the application roles ... iodine based agents used for over half a century ... imaging agents have witnessed sea changes, revolutionizing in the ...
(Date:9/19/2014)... (PRWEB) September 19, 2014 ... ligand assays used for detection and quantification of ... given sample. Driven by steady expansion in immunodiagnostics ... the global immunoassay systems market has evolved remarkably ... conditions, such as diabetes, cardio-vascular ailments, infectious diseases, ...
(Date:9/19/2014)... September 19, 2014 The ... traditional Scandinavian style of eating, is making ... like Diet Doc’s medical weight loss ... and eating good food which leads to ... on teaching patients to understand how diet ...
(Date:9/19/2014)... September 19, 2014 The Relaxation ... years to 2014. Industry operators were able to mass ... period, as well as establish distribution contracts with nation-wide ... large part to its novelty; energy drinks have only ... time, industry operators have been able to establish brands ...
(Date:9/19/2014)... 19, 2014 Recent financial data ... industry increased their sales by 7% in the last ... trucking industry can be used as a bellwether to ... whole. This data has been proven to show trends ... freight transportation. Other non-trucking data is largely influenced by ...
Breaking Medicine News(10 mins):Health News:New Clinical Applications and Advanced Imaging Capabilities Drive Growth in the Imaging Agents Market, According to New Report by Global Industry Analysts, Inc. 2Health News:New Clinical Applications and Advanced Imaging Capabilities Drive Growth in the Imaging Agents Market, According to New Report by Global Industry Analysts, Inc. 3Health News:New Clinical Applications and Advanced Imaging Capabilities Drive Growth in the Imaging Agents Market, According to New Report by Global Industry Analysts, Inc. 4Health News:Growing Preference for Non-Invasive Diagnostics Spurs Growth in the Global Immunoassay Systems Market, According to New Report by Global Industry Analysts, Inc. 2Health News:Growing Preference for Non-Invasive Diagnostics Spurs Growth in the Global Immunoassay Systems Market, According to New Report by Global Industry Analysts, Inc. 3Health News:Growing Preference for Non-Invasive Diagnostics Spurs Growth in the Global Immunoassay Systems Market, According to New Report by Global Industry Analysts, Inc. 4Health News:Diet Doc’s Medical Weight Loss Programs Announce Diet Plans Based on the Same Principles as the New Nordic Diet 2Health News:Diet Doc’s Medical Weight Loss Programs Announce Diet Plans Based on the Same Principles as the New Nordic Diet 3Health News:Diet Doc’s Medical Weight Loss Programs Announce Diet Plans Based on the Same Principles as the New Nordic Diet 4Health News:Relaxation Drink Production in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Relaxation Drink Production in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:LeaseQ Announces Good News For The Truck Leasing Industry As Truck Rentals In The U.S Continues to Gain Traction 2Health News:LeaseQ Announces Good News For The Truck Leasing Industry As Truck Rentals In The U.S Continues to Gain Traction 3
... If war is too serious a matter to be left in ... be left to the care of labour department officials. At least ... ,Latest trends show that agencies like the Occupational Safety and ... of the industries than with the safety of the workers themselves. ...
... Despite being safe, anti-anginal medication Ranolazine has not been ... such as death// , heart attack or recurrent ischemia ... the treatment of acute coronary syndromes (ACS), the risk ... used for patients with chronic angina, but because of ...
... the body’s genetic repair system may cause Huntington’s disease, ... destroying their nervous system. Until now, no one knew ... ,"We showed that when single-strand breaks in DNA ... continued to add extra replacement segments," explains Cynthia McMurray, ...
... Center have zeroed in on a crucial gene, thought ... cancer and resistance// to long-term estrogen deprivation. The gene ... breast cancer reappearance, and would enable a good idea ... ,The research targeted breast cancer cells which had ...
... sentence is being questioned. A study by Plos medicine reveal that ... by the UK based Lancet in 2005. ,This injection ... federal government but many have put a stop to it as ... one drug to induce sleep, the second to stop breathing and ...
... die due to cancer every day, Health Minister Anbumani Ramadoss ... cases in the country were due to tobacco consumption. ... are due to tobacco. The relationship between oral cancer and ... which 91 percent of oral cancers in Southeast Asia are ...
Cached Medicine News:Health News:Overseeing Agency Indifferent to Workplace Safety in US 2Health News:Anti-anginal Drug Not Effective in Reducing Major Cardiac Events 2Health News:Researchers Discovers DNA Repair as Key to Huntington's Disease 2Health News:Execution by Lethal Injection Questioned 2
Adjustable lid speculum angled 45 degrees with 17 mm curved solid blades and aspiration ports to remove excess fluid from around the eye during ocular procedures....
Open 11 mm blades. Dull finish. Most popular size or model....
Open 15 mm blades with lifting wings manipulation of I/A cannulas, knives, instrumentation, etc. Screwlocking mechanism. Dull finish....
Angled for temporal approach. Solid 14 mm blades. Dull finish....
Medicine Products: